Of particular relevance (Figure 8E), Topoisomerase II alpha (TOP2A) is a target for anti-cancer drugs56, LAG3 is a checkpoint inhibitor57, SLAMF7 is targeted by the myeloma immunotherapy drug Elotuzumab65, PTGS2 is a target for anti-inflammatory drugs with a role in inflammatory diseases and cancer66. Here, LAG3 is linked to plasma cell myeloma.